Abstract
Idiopathic IgA Nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis worldwide. All races with the exception of Blacks and Indians are involved. Families with two or more relatives affected by IgAN may be observed in 15-20% of pedigrees of IgAN patients. Genome wide linkage study has been considered the most promising approach to identify IgAN susceptibility genes. Therefore, some European investigators constituted the European IgAN Consortium which was initially funded by the European Union. Data from linkage analysis studies, family association studies and case-control association studies are reported. To date, the Consortium has identified two loci (located on chromosomes 4q26-31 and 17q12-22), in addition to the previous study which described the first IgAN locus on chromosome 6q22-23. The functional mapping of genes involved in the disease proceeds from the identification of susceptibility loci identified by linkage analysis (step 1) to the isolation of candidate genes within gene disease-susceptibility loci, after obtaining information by microarray analysis carried out on peripheral leukocytes and renal tissue samples (step 2). Then, the process will proceed from the design of RNA interference-agents against selected genes (step 3) to the application of systematically tested effect of RNA agents on functional cellular assay (step 4). The above combined high-throughput technologies will give information on the pathogenic mechanisms of IgAN. In addition, these data may indicate potential targets for screening, prevention and early diagnosis of the disease and more appropriate and effective treatment.
| Original language | English |
|---|---|
| Title of host publication | Contributions to Nephrology |
| Pages | 80-89 |
| Number of pages | 10 |
| Volume | 157 |
| DOIs | |
| Publication status | Published - 2007 |
Publication series
| Name | Contributions to Nephrology |
|---|---|
| Volume | 157 |
| ISSN (Print) | 03025144 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Searching for IgA nephropathy candidate genes : Genetic studies combined with high throughput innovative investigations. / Schena, F. P.; Cerullo, G.; Torres, D. D.; Zaza, G.; Cox, S.; Bisceglia, L.; Scolari, F.; Frascà, G.; Ghiggeri, G. M.; Amoroso, A.; Schena, F. Paolo.
Contributions to Nephrology. Vol. 157 2007. p. 80-89 (Contributions to Nephrology; Vol. 157).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Searching for IgA nephropathy candidate genes
T2 - Genetic studies combined with high throughput innovative investigations
AU - Schena, F. P.
AU - Cerullo, G.
AU - Torres, D. D.
AU - Zaza, G.
AU - Cox, S.
AU - Bisceglia, L.
AU - Scolari, F.
AU - Frascà, G.
AU - Ghiggeri, G. M.
AU - Amoroso, A.
AU - Schena, F. Paolo
PY - 2007
Y1 - 2007
N2 - Idiopathic IgA Nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis worldwide. All races with the exception of Blacks and Indians are involved. Families with two or more relatives affected by IgAN may be observed in 15-20% of pedigrees of IgAN patients. Genome wide linkage study has been considered the most promising approach to identify IgAN susceptibility genes. Therefore, some European investigators constituted the European IgAN Consortium which was initially funded by the European Union. Data from linkage analysis studies, family association studies and case-control association studies are reported. To date, the Consortium has identified two loci (located on chromosomes 4q26-31 and 17q12-22), in addition to the previous study which described the first IgAN locus on chromosome 6q22-23. The functional mapping of genes involved in the disease proceeds from the identification of susceptibility loci identified by linkage analysis (step 1) to the isolation of candidate genes within gene disease-susceptibility loci, after obtaining information by microarray analysis carried out on peripheral leukocytes and renal tissue samples (step 2). Then, the process will proceed from the design of RNA interference-agents against selected genes (step 3) to the application of systematically tested effect of RNA agents on functional cellular assay (step 4). The above combined high-throughput technologies will give information on the pathogenic mechanisms of IgAN. In addition, these data may indicate potential targets for screening, prevention and early diagnosis of the disease and more appropriate and effective treatment.
AB - Idiopathic IgA Nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis worldwide. All races with the exception of Blacks and Indians are involved. Families with two or more relatives affected by IgAN may be observed in 15-20% of pedigrees of IgAN patients. Genome wide linkage study has been considered the most promising approach to identify IgAN susceptibility genes. Therefore, some European investigators constituted the European IgAN Consortium which was initially funded by the European Union. Data from linkage analysis studies, family association studies and case-control association studies are reported. To date, the Consortium has identified two loci (located on chromosomes 4q26-31 and 17q12-22), in addition to the previous study which described the first IgAN locus on chromosome 6q22-23. The functional mapping of genes involved in the disease proceeds from the identification of susceptibility loci identified by linkage analysis (step 1) to the isolation of candidate genes within gene disease-susceptibility loci, after obtaining information by microarray analysis carried out on peripheral leukocytes and renal tissue samples (step 2). Then, the process will proceed from the design of RNA interference-agents against selected genes (step 3) to the application of systematically tested effect of RNA agents on functional cellular assay (step 4). The above combined high-throughput technologies will give information on the pathogenic mechanisms of IgAN. In addition, these data may indicate potential targets for screening, prevention and early diagnosis of the disease and more appropriate and effective treatment.
UR - http://www.scopus.com/inward/record.url?scp=34249053524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249053524&partnerID=8YFLogxK
U2 - 10.1159/0000102308
DO - 10.1159/0000102308
M3 - Conference contribution
C2 - 17495441
AN - SCOPUS:34249053524
SN - 3805582862
SN - 9783805582865
VL - 157
T3 - Contributions to Nephrology
SP - 80
EP - 89
BT - Contributions to Nephrology
ER -